"First: Warby Medical completed hundreds of millions of dollars of B-plus round financing, to create a total stroke solution, based on the local to win overseas opportunities.

Read: Hundreds of Millions of Financing Helps Stroke Solve PerfectLy. On August 11,
, Shanghai Warby Medical Technology Co., Ltd. (Or: Warby Medical, Wallaby Medical) announced the completion of hundreds of millions of yuan of B-plus round financing, the proceeds of which are mainly used to promote the development of its global blood and ischemic stroke treatment portfolio, deepen its overseas market layout in Europe, America, Japan, South America and other overseas markets, support the company's ongoing two clinical trials, and lay a solid foundation for the domestic and ischemic stroke products to be available in China by 2021.
it is understood that the current round of financing by citic Medical Fund, the existing investment institutions shareholders Ma Xing Investment, the former jellyfish fund and Chang'an private capital additional investment. Founded in 2016,
Woby Medical is a medical technology company focused on neuro-intervention, developing and producing innovative international products for the treatment of high-end vascular diseases, dedicated to saving the lives of more stroke patients and aiming to become a global leader in stroke therapy.
based on the high incidence of stroke in Asia and China as the world's largest market for stroke medical care, the company was founded with its headquarters and production base in Shanghai Medical Valley, China, and a wholly-owned research and development subsidiary (R ampditin) in California, USA.
it is worth mentioning that Warby Medical's "Warby cerebrovascular aneurysm embolism spring ring" is the first and currently the only one in the United States FDA, EU CE and Japan PMDA certified nerve embolism intervention medical products, and in the second half of 2019 officially listed in the United States, has now entered UCLA, Kaiser (Kaiser Medical Group), Klinikum, BHRHospital and other internationally renowned hospitals, has been recognized by foreign experts and hospitals.
in the domestic registration, the company and Tiantan Hospital, Xuanwu Hospital, Huashan Hospital and other top hospitals to carry out clinical trials, in order to quickly open the domestic market to do a good job of preparation.
, as a Company based in China and globally, Warby Medical brings together talented people from all over the world.
, Mr. Michael Alper, CEO of Warby, has Chinese skills in English, Chinese, Japanese, Spanish, etc., has worked in Medtronic Marketing Department, in the United States, Europe, South America, Japan and other regions have a wealth of sales channels accumulation and good partnership.
company's strong technical strength, research and development director Earl F. Bardsley has 30 years of experience in interventional research and development, is the world leader in neurovascular research and development, has been in Medtronic, Poco, Microvention and other companies as the head of intervention al-Genproduct research and development, research and development capabilities outstanding.
management's global vision, strong research and development capabilities, and the first launch of the European and American markets have laid a solid foundation for Warby to become a leading global neuro-intervention company.
from "spring ring" to "thrombosis catheter", the comprehensive layout of stroke solution intracranial spring ring is a new generation of medical means and products for patients with hemorrhagic stroke (intracranial aneurysm) to replace traditional treatment, and the surgical placement devices essential for interventional treatment belong to the three types of medical devices at the highest level in the country.
global perspective, the annual implant volume of spring rings exceeds one million, and the single-product market size exceeds 10 billion yuan.
facing a huge billion-dollar market, several years ago domestic enterprises have been involved in intracranial spring ring research and development, but because of the neurovascular intervention treatment needs ultra-high accuracy and the lowest error range, is the most challenging vascular area in clinical medicine, in product development, materialscience, quality standards, production and processing, etc. have very high requirements, and domestic intracranial spring ring push rod and spring ring relatively stiff, slow relief mechanism, quality and reliability of the current domesticization rate is still less than 10%
Woby Medical after unremitting independent research and development, the introduction of the first mechanical relief spring ring, using the industry's thinnest platinum wire winding, covering more than a hundred specifications, only a simple folding action can be released, without the need to configure an external relief.
the compliance of the spring ring, basket reliability, closing ring softness, release time and release reliability and complication incidence of key technical points can achieve or even better than similar products abroad, excellent performance.
noteworthy is that the mechanical relief spring ring has been approved by the U.S. FDA and European CE, as well as Japan, Peru, Argentina, Israel and other countries product registration certificate.
has now completed clinical trials in China and is on follow-up.
the spring ring overseas pricing and Medtroni and other international first-line brands similar, clinical feedback is good.
this also means that the spring ring produced in China has been internationally recognized, for Warby in the field of stroke intervention in the field of domestic substitution to win the first opportunity.
in addition to the intracranial spring ring, Warby Medical has been developing and developing innovations to introduce a thrombosis catheter.
thrombosis catheter is recognized in the industry as the most difficult to manufacture, with high requirements for its antifolding properties, in-tube coating, passability, etc.
different from other domestic neuro-intervention companies focused on the field of hydrant stent products, Warby chose the most technically difficult suction catheter direction, Warby said: "suction catheters in clinical applications more convenient for doctors to operate, reliability applicability effectiveness is more advantage, has been considered the future trend of mechanical thrombosis, the current U.S. market 80% of ischemic stroke device treatment will be used first with the suction catheter."
suction ducts are much more complex in product development than hydrant stents, and in the manufacturing process requires precise quality standards and special technology applications, based on confidence in the company's research and development, production capacity, Warby chose the first market potential is the greatest but also recognized as the most difficult areas.
"Warby Medical's intracranial thrombosis catheter is a single cavity, single tube diameter, soft and stiffness gradient composite catheter.
the product has a large tube cavity (0.071), and in the current internal cavity of similar products with the smallest outer diameter, providing ultra-smooth transport and near-end control, in the suction flow and head-end suction force to achieve the international leading level.
at present, Warby Medical's intracranial thrombosis catheter is applying for FDA and CE certification, domestic registration has been in Xuanwu Hospital and other clinical trials.
intracranial thrombosis catheter is another heavyweight fist product for Warby Medical, enriching the company's product line in the field of brain intervention devices and greatly enhancing Warby's technical strength and brand image.
in the product reserve, Warby to create a complete line of ischemic, hemorrhagic and path products, followed by more heavy products will be launched, for domestic and foreign patients to bring the world's leading level of neurointervention overall solutions.
10 billion nerve intervention market, domestic replacement of the new king of China is one of the world's highest incidence of stroke, and stroke incidence rate is increasing year by year.
the number of stroke cases in China, where the death rate per 100,000 people exceeds cardiovascular disease, is expected to reach 31.77 million in 2030.
neurointervention is an important part of interventional medicine, the diagnosis and treatment of cerebrovascular vessels is difficult and wide-ranging, and is regarded as the jewel in the crown of interventional surgery.
the rapid development of the nerve intervention industry, the size of the domestic market is expected to exceed 30 billion yuan in 2025.
but the market is monopolized by foreign capital, hemorrhage and ischemic market localization rate is less than 10%.
but fortunately, Warby Medical as a domestic brand, although the creation of a short time, but its reverse trend and bend overtaking, product research and development directly aimed at the latest international frontier, neuro-intervention products have been widely recognized by international and domestic experts.
"The U.S. market is very 'honest', they are very high in technology and product quality requirements, Warby's products can successfully open the U.S. market enough to demonstrate its technological advancement and quality stability."
" Warby Medical told Arterial Network, "We have more than a dozen clinical hospitals in the country, used experts said that Warby products and imports are not different, a better way of relief, Warby products forensic selling full of expectations."
"Wallby Medical's vision is to save more stroke patients, and driven by that vision, the company is committed to making the best stroke products in the world."
from the current Woby medical products landing situation, the company has achieved a phased success: in the European and American markets completed the product launch, and the international market recognition.
company is expected to get the domestic registration certificate in 2021, and the trend to start the Chinese market, with a large number of overseas clinical data accumulation and verification, the company will have a first-mover advantage in China.
through the rapid occupation of the domestic market, Warby Medical will use international advanced technology and research and development concept system, will build itself into an international research and development and production capacity of enterprises, and ultimately benefit Stroke patients in China and the world.
," said Michael Alper, founder and chief executive of Warby Healthcare,
, "the involvement of new and old investors has greatly encouraged our passion for clinical product development.
this also shows that they sincerely recognize our roots in China, the world of service company philosophy.
our team will adhere to technological innovation and product innovation.
we have the confidence to be a global leader in overall solutions in the stroke field.
" Ms. Cai Hua, General Manager of CITIC Medical Fund, has over 20 years of experience in operation, investment and financing and merger integration in the medical health sector.
she said: "Stroke is a disease with a high incidence and disability rate in China, which places a great burden on both patients and society."
neurointervention is another market with great potential for medical devices after coronary intervention.
Woby Medical Layout Neuro-Intervention Full Product Line to Address Hemorrhagic and Ischemic Stroke, is an area of focus for our fund.
neurointervention is a passive medical device pyramid products, technology and quality is the soul of the enterprise, we value the technical accumulation of Warby and the quality of products to improve the quality of the characteristics, the high evaluation of china and the United States and China's top hospital experts give us enough confidence that Warby can become a leading global company in the field of neurointervention. Li Xin, Managing Director of
" Maxing Investments, said: "Maxing Investment sits on plant intervention supplies, and for more than two years, as a member of the Board of Directors, we have witnessed the remarkable growth of Warby in the field of neuro-intervention, both in terms of clinical progress in the product and in the process of commercialization, reflecting the characteristics of an innovative company's leading industry."
especially the company's products as the first overseas developed countries market to achieve large-scale clinical practical application of nerve intervention supplies, and achieved very positive medical feedback, impressive.
we continue to be bullish on the Wallabies' leadership in the field of neuro-intervention and continue to invest additionally.
", Wallaby Medical is a China-based, globally-based, innovative platform company for medical devices focused on neurointerventions, dedicated to the development and commercialization of medical device products for the treatment of stroke.
Wallaby AvenirTM Spring Ring System, the first product of Warby Medical, is a highly technically differentiated neuroembolic spring coil system used to treat intracranial aneurysms and other neurovascular abnormalities, becoming the first domestic spring ring products sold in the United States.
company in the field of neuro-intervention is also in the field of global vision layout, AvenirTM has now been approved by the United States FDA510K, the European Union CE certification and the Ministry of Health, Labour and Welfare OF Japan PMDA approval, has been in more than 12 countries or regions to achieve commercial use.
Woby Medical's thrombosis catheters have been activated into FDA registration, and several other high-tech new products are currently under development.
about CITIC Medical Fund CITIC Medical Fund is CITIC's equity investment management platform focused on the field of pharmaceutical health, and is committed to building an enabling pharmaceutical industry fund with deep industry integration capabilities.
core team consists of industry experts with senior operational experience in multinational pharmaceutical companies and financial experts who have deep experience in the financial sector.
about Maxing Investment snr. currently manages four RMB funds and one US dollar fund, mainly in the investment areas of consumer, medical and technology;
on the former jellyfish fund Qianhai Equity Investment Parent Fund was successfully established in December 2015 and currently raises 28.5 billion yuan.
fund management company in the State Administration for Industry and Commerce nuclear name, the full name "Front Haizhou Asset Management Co., Ltd."
the successful establishment of the former jellyfish fund marks the completion of the fourth of the eight tasks of the State Council's pre-sea financial innovation.
former jellyfish fund is currently the largest commercial raising mother fund, but also the largest domestic fund-raising venture capital and private equity investment fund.
the former jellyfish fund gathered the current domestic strong, influential, interactive resources of investorSLp, including four categories: government, insurance and financial investment institutions, well-known enterprises and listed companies, individuals with commercial achievements.
chang'an Private Capital Chang'an Private Capital is an investment institution that uses its own foreign currency capital for domestic and foreign equity investments, focusing on low risk, high return, potential for market-oriented investment, high endogenous growth and the potential to become an industry leader.
has accumulated 15 years of investment experience and lessons, 30 invested companies, 80% of the profit exit, of which 10 have been successfully listed in A-shares or overseas, including Watson Bio (300142), Orikin (SZ:002701), Superpower Power (HK:0095) 1), Longping Gaoke (SZ:000998), Zhongju High-tech (SH:600872), Kaiyuan Electrical and Mechanical (300140), Western Cement (HK:02233), and 2 other in the A-share listing channel.
.